Tachyon operates with a dedicated internal core development team and a world-class external network of expertise. We enlist the support of leading experts in their field, from pharmacology to manufacturing, and from science to clinical to work with us in a dynamic and fast-paced development environment. Tachyon selects from the best preclinical and clinical contract research organizations (CRO) and outstanding contract manufacturing organizations (CMO) to achieve one goal – advance our innovative programs with scientific rigor, speed and quality. This highly flexible and effective model allows us to achieve our mission to bring new cancer drugs to patients in need as fast as possible.
FRANK PERABO, MD, PHD
Chief Executive Officer
Dr. Perabo is a Life Science Executive and Entrepreneur with over 20 years’ R&D experience in Pharma and Biotech. He has founded and co-founded several Biotech companies (Barricade Therapeutics, MAIA Biotechnology). He has also served as Chief Medical Officer and Executive Vice President of Development of ESSA Pharmaceuticals and Executive Director at Astellas Pharma where he was instrumental in the development and worldwide approval of XTANDI® (Enzalutamide). Dr. Perabo has a proven track record in leading successful early and late-phase clinical development programs with extensive regulatory interactions globally. Dr. Perabo obtained his medical training at the Universities of Munich, Freiburg and Bonn after graduating magna cum laude from medical school at the University of Munich, with a PhD in Cancer Biology.
SUMAN BHATTACHARYA, PHD
Sr VP, Data Science & Development Strategy
Dr. Bhattacharya brings 23-plus years of experience to Tachyon as an executive consultant. His industry knowledge is underscored by a proven track record in Data Science, oncology clinical development, clinical pharmacology and cross-functional leadership. Before joining Tachyon, Dr. Bhattacharya was SVP of Data Sciences at Ventyx Biosciences and held a similar role at a Stealth Biotech Company. Prior to that, he served as VP and Head of Biometrics at Allogene Therapeutics and at Medivation until Pfizer’s successful acquisition. Notably, he played an important role in shaping the development strategy and securing approvals for Xtandi® (AR inhibitor) for prostate cancer and Talazoparib® (PARP inhibitor) for triple-negative breast cancer.
Before Medivation, he spent several years at Genentech where he made important contributions to the development of Avastin® (VEGF inhibitor) and Vemurafenib® (BRAF inhibitor). His leadership roles at Medivation, Genentech, and the Stealth Pharma Company encompassed responsibilities such as development team leadership and leading teams through the NDA/sNDA/BLA/sBLA filing process.
Dr. Bhattacharya completed his Ph.D. in Biostatistics and Statistical Genetics from UCLA and holds a Master of Science in Applied Statistics and Operations Research from Bowling Green State University, Ohio.
Sr VP, Regulatory Affairs
Ms. Marchione joined Tachyon as an executive consultant after 35 years of working with multiple pharmaceutical companies, where she primarily focused on regulatory strategy to support the development and commercialization of drugs. As an independent contractor, she has worked with a variety of clients, resulting in approvals for drugs targeting hematology and oncology indications. Prior to contracting, Ms Marchione held roles of increasing responsibility including Oncology Head at Cephalon, Teva, Innocoll and Tetralogic. She holds a B.S. in Biology from Villanova University.
CHAN CHANDHASIN, PHD
VP, Program Management
Dr. Chandhasin has more than 15 years of diversified experience in the field of oncology in leading academic, industry, and health care organizations. Prior to joining Tachyon, she served as Chief Clinical Officer at Medicenna Therapeutics where she oversaw clinical programs related to data analysis, scientific communications, and in-vitro diagnostic development. Prior to that she served as the Director of Medical Affairs at ESSA Pharmaceuticals and held Program Management positions at ApoCell, Inc., Christiana Care Health Systems, and M.D. Anderson Cancer Center. Dr. Chandhasin received a Ph.D. in Molecular and Cellular Biology from Tulane University School of Medicine and completed her post-doctoral fellowship at Baylor College of Medicine.
VP, Clinical Operations
Sr Dir, Non-Clinical Science & Pharmacology
Assist Dir, Planning Administration & Logistics
Ms. Porter has over 15 years of combined administrative experience between healthcare and technology industries. Prior to joining Tachyon, she served as Executive Assistant at HCA Houston Healthcare. There she leveraged her analytical and organizational skills to assist in the overall operational performance of the teams she supported. At Tachyon, Isabel is leading multiple organizational development initiatives, with the goal to promote and maintain operational excellence. Isabel is a US Army veteran who served in Operation Iraqi Freedom and applies those lessons of service, dedication, and attention to detail to Tachyon’s mission.